Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Maintains Neutral on Enfusion, Raises Price Target to $10

Author: Benzinga Newsdesk | December 20, 2023 03:18pm
Piper Sandler analyst Sumeet Mody maintains Enfusion (NYSE:ENFN) with a Neutral and raises the price target from $9 to $10.

Posted In: ENFN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist